U.S. markets closed
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • Dow 30

    34,935.47
    -149.06 (-0.42%)
     
  • Nasdaq

    14,672.68
    -105.59 (-0.71%)
     
  • Russell 2000

    2,226.25
    -13.78 (-0.62%)
     
  • Crude Oil

    73.81
    +0.19 (+0.26%)
     
  • Gold

    1,812.50
    -18.70 (-1.02%)
     
  • Silver

    25.55
    -0.23 (-0.90%)
     
  • EUR/USD

    1.1872
    -0.0024 (-0.20%)
     
  • 10-Yr Bond

    1.2390
    -0.0300 (-2.36%)
     
  • GBP/USD

    1.3908
    -0.0050 (-0.35%)
     
  • USD/JPY

    109.6500
    +0.1890 (+0.17%)
     
  • BTC-USD

    41,684.50
    +53.01 (+0.13%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

Inari Medical Reports Second Quarter 2020 Financial Results

·8 min read

IRVINE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its second quarter ended June 30, 2020.

Second Quarter Highlights:

  • Treated more patients in the second quarter of 2020 than in the first quarter of 2020, despite COVID-19 headwinds

  • Reported revenue of $25.4 million in the second quarter of 2020, a 152% increase over the same quarter last year

  • Established a weekly online educational series, the Clot Warrior Academy, attended to date by more than 600 physicians and 200 nurses and technicians

  • Completed an initial public offering of 9.4 million shares, raising $163.0 million in net proceeds

“The second quarter was difficult for so many companies and so many people, for all the reasons we know. Our team has responded to the challenges and risen to the occasion. Our employee training and physician education programs are better, our supply chain and production capacity are more robust, our pipeline is broader and deeper, and our relationships with our physicians, customers, and with each other are stronger than before the pandemic. Importantly, our team and physician partners found a way to treat more patients in the second quarter than in any previous quarter. In these humbling and uncertain times, we are thankful for the clarity of a mission and a cause bigger than ourselves and business,” said Bill Hoffman, Chief Executive Officer.

Second Quarter 2020 Financial Results
Revenue was $25.4 million for the second quarter of 2020, compared to $27.0 million for the prior quarter and $10.1 million for the second quarter of 2019. The increase from last year was driven by continued US commercial expansion and increased product adoption.

Gross profit for the second quarter of 2020 was $21.9 million compared to $8.7 million for the second quarter of 2019. Gross margin declined slightly to 86.3% for the second quarter of 2020, compared with 86.8% in the same quarter last year. In the current quarter, the positive impact of manufacturing efficiencies was partially offset by idle production capacity costs resulting from the COVID-19 pandemic.

Operating expenses were $22.5 million for the second quarter of 2020, compared with $9.4 million in the same quarter last year. The increase was driven primarily by personnel-related expenses to fund expansion of the commercial, research and development, clinical and support organizations, as well as expenses related to being a public company.

Net loss was $3.8 million for the second quarter of 2020 and net loss per share was $0.16 on a weighted-average basic and diluted share count of 24.3 million, compared to $1.0 million and a net loss per share of $0.17 on a weighted-average basic and diluted share count of 5.8 million in the same period of the prior year. Although the loss from operations was modestly improved at $603,000 in the current quarter, compared to $642,000 in the same quarter last year, the change in fair value of warrant liabilities of $2.9 million contributed to the higher net loss in the current quarter.

Cash and cash equivalents were $194.8 million as of June 30, 2020, which includes net cash proceeds of $163.0 million from its initial public offering completed in May 2020.

Outlook and COVID-19
Due to uncertainty surrounding the COVID-19 pandemic, Inari Medical will not provide financial guidance for the remainder of 2020 at this time. Management anticipates providing an update at the time of its third quarter earnings announcement, to the extent practicable, based on available information at that time.

Webcast and Conference Call Information
Inari Medical will host a conference call to discuss the second quarter financial results after market close on Tuesday, August 11, 2020 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The conference call can be accessed live over the phone (833) 519-1265 for U.S. callers or (914) 800-3838 for international callers, using conference ID: 6859088. The live webinar can be accessed at https://ir.inarimedical.com.

About Inari Medical, Inc.
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.

Inari is focused on treating venous thromboembolism and improving the quality of life of patients suffering from this disease by safely and effectively removing blood clots. Inari has developed two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The ClotTriever system is 510(k)-cleared by the FDA for thrombectomy in the peripheral vessels and is used to treat patients suffering from deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism.

Forward Looking Statements
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements are based on Inari’s current expectations, forecasts and assumptions, are subject to inherent uncertainties, risks and assumptions that are difficult to predict and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Quarterly Report on Form 10-Q for the period ended June 30, 2020 and in its other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari.

Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com



INARI MEDICAL, INC.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share data)
(unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2020

2019

2020

2019

Revenue

$

25,392

$

10,072

$

52,345

$

17,017

Cost of goods sold

3,487

1,331

6,193

2,262

Gross profit

21,905

8,741

46,152

14,755

Operating expenses

Research and development

3,628

1,580

6,646

2,789

Selling, general and administrative

18,880

7,803

35,273

13,229

Total operating expenses

22,508

9,383

41,919

16,018

Income (loss) from operations

(603

)

(642

)

4,233

(1,263

)

Other income (expense)

Interest income

146

24

201

48

Interest expense

(463

)

(229

)

(809

)

(456

)

Change in fair value of warrant liabilities

(2,884

)

(118

)

(3,317

)

(242

)

Total other expenses

(3,201

)

(323

)

(3,925

)

(650

)

Net income (loss) and comprehensive income (loss)

$

(3,804

)

$

(965

)

$

308

$

(1,913

)

Net income (loss) per share

Basic

$

(0.16

)

$

(0.17

)

$

0.02

$

(0.34

)

Diluted

$

(0.16

)

$

(0.17

)

$

0.01

$

(0.34

)

Weighted average common shares used to compute net income (loss) per share,

Basic

24,295,900

5,753,332

15,339,755

5,676,995

Diluted

24,295,900

5,753,332

47,362,292

5,676,995



INARI MEDICAL, INC.
Condensed Consolidated Balance Sheets
(in thousands, except share data)
(unaudited)

June 30,
2020

December 31,
2019

Assets

Current assets

Cash and cash equivalents

$

194,836

$

23,639

Accounts receivable, net

15,392

11,302

Restricted cash

50

50

Inventories, net

5,620

3,953

Prepaid expenses and other current assets

3,866

464

Total current assets

219,764

39,408

Property and equipment, net

4,176

3,331

Restricted cash

338

338

Deposits and other assets

76

1,469

Total assets

$

224,354

$

44,546

Liabilities, Mezzanine Equity and Stockholders' Equity (Deficit)

Current liabilities

Accounts payable

$

2,294

$

2,549

Payroll-related accruals

7,223

5,225

Accrued expenses and other current liabilities

1,385

1,096

Total current liabilities

10,902

8,870

Notes payable, net

29,582

19,481

Warrant liabilities

1,169

Total liabilities

40,484

29,520

Commitments and contingencies

Mezzanine equity

Redeemable convertible preferred stock, par value $0.001, no shares authorized, issued, and outstanding as of June 30, 2020; 32,225,227 shares authorized, 31,968,570 shares issued and outstanding as of December 31, 2019; aggregate liquidation preference of zero as of June 30, 2020 and $54,415 as of December 31, 2019

54,170

Stockholders' equity (deficit)

Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2020; no shares authorized, issued, and outstanding at December 31, 2019

Common stock, $0.001 par value, 300,000,000 and 49,019,607 shares authorized as of June 30, 2020 and December 31, 2019, respectively; 48,360,081 and 6,720,767 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively

48

7

Additional paid in capital

224,726

2,061

Accumulated deficit

(40,904

)

(41,212

)

Total stockholders' equity (deficit)

183,870

(39,144

)

Total liabilities, mezzanine equity and stockholders' equity (deficit)

$

224,354

$

44,546